Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With 
BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo
Dirk Schadendorf,1 Reinhard Dummer,2 Axel Hauschild,3 Mario Santinami,4 Victoria Atkinson,5 Mario Mandalà,6 Vanna Chiarion-Sileni,7 James Larkin,8 Marta Nyakas,9 Caroline Dutriaux,10 Andrew Haydon,11 Laurent Mortier,12 Caroline Robert,13 Jacob Schachter,14 
Christine-Elke Ortmann,15 Egbert de Jong15 Eduard Gasal,16 Richard Kefford,17 John M. Kirkwood,18 Georgina V. Long19
1University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany; 2University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; 3University Hospital Schleswig-Holstein, Kiel, Germany; 4Fondazione Istituto Nazionale Tumori, Milano, Italy; 5Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Woolloongabba, QLD, Australia; 6Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; 
7Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; 8The Royal Marsden NHS Foundation Trust, London, United Kingdom; 9Oslo University Hospital, Oslo, Norway; 10Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; 11The Alfred Hospital, Melbourne, VIC, Australia; 12Université de Lille, INSERM U 1189, CHRU Lille, Lille, France; 13Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France; 14Ella Lemelbaum 
Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 15Novartis Pharma AG, Basel, Switzerland; 16Novartis Pharmaceuticals Corporation, East Hanover, NJ; 17Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, NSW, Australia; 18Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; 
19Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia

Background
• In the double-blind, randomized, phase 3 COMBI-AD trial 

(NCT01682083), 12 months of adjuvant dabrafenib + trametinib 
led to significant improvement in relapse-free survival (RFS) and 
distant metastasis-free survival (DMFS) vs placebo (RFS hazard 
ratio [HR], 0.47; P < .001; DMFS HR, 0.51; P < .001) in patients with 
resected BRAF V600–mutant stage III melanoma1,2

 – In the dabrafenib + trametinib arm, 3- and 4-year RFS rates 
were 59% and 54%, respectively1

 – In the dabrafenib + trametinib arm, 3- and 4-year DMFS rates 
were 71% and 67%, respectively1

• A cure-rate model estimated that treatment with dabrafenib + 
trametinib led to a 17% absolute increase in the proportion of 
patients who will remain relapse free long term1

• An interim analysis of overall survival (OS) showed a clinically 
meaningful improvement with dabrafenib + trametinib vs placebo 
(HR, 0.57 [95% CI, 0.42-0.79])2

• The safety profile of the combination was consistent with that 
observed in patients with metastatic melanoma2

• Based on these trial results, dabrafenib + trametinib has been 
approved by multiple regulatory agencies globally, including the 
US Food and Drug Administration and European Commission, 
for the treatment of patients with resected BRAF V600–mutant 
stage III melanoma3-6

• Previous subgroup analysis of RFS demonstrated similar 
treatment benefit favoring dabrafenib + trametinib regardless 
of baseline factors, including1:

 – Disease stage (per American Joint Committee on Cancer 
[AJCC] 7th and 8th editions)

 – Micrometastases/macrometastases

 – Ulceration of the primary tumor

• We present an updated analysis evaluating the association 
between baseline disease characteristics and RFS to identify 
patient subgroups likely to benefit from adjuvant treatment

Methods
• COMBI-AD was a randomized, phase 3 study of dabrafenib + 

trametinib in patients with completely resected stage III BRAF 
V600E/K–mutant melanoma (Figure 1)1,7

Figure 1. Study Design
N=870 Treatment: 12 monthsa

1:1

R
A
N
D
O
M
I
Z
A
T
I
O
N

Key eligibility criteria

• Completely resected, high-risk
stage IIIA (lymph node metastasis
> 1 mm), IIIB, or IIIC cutaneous
melanoma

• BRAF V600E/K mutation

• Surgically free of disease
≤ 12 weeks before randomization

• ECOG performance status 0 or 1

• No prior radiotherapy or systemic 
therapy

Stratification
• BRAF mutation status (V600E, V600K)

• Disease stage (AJCC 7; IIIA, IIIB, IIIC)

• Primary endpoint: RFSd

• Secondary endpoints: OS, DMFS, FFR, safety

Dabrafenib 150 mg BID + 
trametinib 2 mg QD

(n = 438)

2 matched placebos

(n = 432)

Follow-upb
until end
of studyc

BID, twice daily; DMFS, distant metastasis–free survival; ECOG, Eastern Cooperative Oncology Group; FFR, 
freedom from relapse; QD, once daily.
a Or until disease recurrence, death, unacceptable toxicity, or withdrawal of consent; b Patients were followed up 
for disease recurrence until the first recurrence and thereafter for survival; c The study will be considered complete 
and final OS analysis will occur when ≈ 70% of randomized patients have died or are lost to follow-up; d New primary 
melanoma considered as an event.

Analysis of the Association of Baseline Factors With RFS
• Within each subgroup, the Kaplan-Meier method was used to 

estimate RFS, and HRs were calculated using a Pike estimator
 – Covariates including age, sex, T stage, N stage, in-transit 

metastases, and histological subtype were analyzed
 – Tumor staging was assessed according to AJCC 7th edition 

criteria

Data Set

• Analyses were based on the data cutoff date for an updated 
analysis of the COMBI-AD study (April 30, 2018)

 – Minimum follow-up was 40 months for 870 enrolled patients 
(dabrafenib + trametinib, n = 438; placebo, n = 432)

Results
• The median age of patients in COMBI-AD was 51 years. Kaplan-

Meier analysis of RFS based on age (< median or ≥ median) 
demonstrated improved RFS in patients treated with dabrafenib + 
trametinib vs placebo regardless of age (Figure 2)

 – Age < 51 years: Median RFS was not reached in the dabrafenib 
+ trametinib arm vs 20.1 months in the placebo arm (HR, 0.51 
[95% CI, 0.38-0.67])

 – Age ≥ 51 years: Median RFS was not reached in the dabrafenib 
+ trametinib arm vs 13.8 months in the placebo arm (HR, 0.49 
[95% CI, 0.38-0.64])

Figure 2. Investigator-Assessed Kaplan-Meier RFS Curves by Age

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

Time From Randomization, months

P
ro

p
o

rt
io

n
 A

liv
e

 a
n

d
 R

e
la

p
se

 F
re

e

32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62

221
217
208
224

D+T < 51 y
D+T ≥ 51 y
PBO < 51 y
PBO ≥ 51 y

No. at risk
209
204
185
202

207
198
160
162

202
189
137
143

196
185
133
130

192
180
121
122

183
171
109
110

177
158
100
103

171
153
100
98

156
142
95
90

151
130
91
87

148
127
89
86

142
120
86
82

140
116
86
80

134
115
85
79

128
114
82
76

124
113
81
76

122
111
76
75

117
110
74
73

116
109
73
72

95
88
61
67

84
77
53
59

77
71
51
56

62
52
39
41

49
43
32
31

35
30
20
24

27
20
12
15

20
14
9
9

9
4
0
4

4
1

2

2
0

1

0

0

Group Events, n (%) Median (95% CI), mo

D+T
< 51 y
≥ 51 y

86 (39)
91 (42)

NR (45.6-NR)
NR (33.2-NR)

0.51 (0.38-0.67)
0.49 (0.38-0.64)

-
-

PBO
< 51 y
≥ 51 y

116 (56)
138 (62)

20.1 (13.8-35.3)
13.8 (11.0-19.6)

D+T vs PBO
HR (95% CI)a

Data cutoff: April 30, 2018.
D, dabrafenib; NR, not reached; PBO, placebo; T, trametinib.
a HR was estimated using Pike estimator. An HR < 1 indicates a lower risk with dabrafenib + trametinib than with 

placebo.

• Kaplan-Meier analysis demonstrated that dabrafenib + trametinib 
improved RFS vs placebo regardless of patients’ sex (Figure 3)

 – Female patients: Median RFS was not reached in the 
dabrafenib + trametinib arm vs 25.5 months in the placebo arm 
(HR, 0.56 [95% CI, 0.42-0.75])

 – Male patients: Median RFS was not reached in the dabrafenib 
+ trametinib arm vs 13.8 months in the placebo arm (HR, 0.45 
[95% CI, 0.35-0.58])

Figure 3. Investigator-Assessed Kaplan-Meier RFS Curves by Sex

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Time From Randomization, months

P
ro

p
o

rt
io

n
 A

liv
e

 a
n

d
 R

e
la

p
se

 F
re

e

32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62

194
244
193
239

D+T female
D+T male
PBO female
PBO male

No. at risk
182
231
176
211

179
226
148
174

172
219
130
150

167
214
124
139

162
210
116
127

157
197
105
114

149
186
101
102

144
180
98
100

134
164
94
91

127
154
93
85

123
152
92
83

118
144
90
78

113
143
88
78

108
141
88
76

103
139
85
73

101
136
85
72

100
133
80
71

98
129
77
70

98
127
76
69

84
99
65
63

73
88
56
56

62
86
56
51

48
66
42
38

39
53
33
30

32
33
23
21

21
26
14
13

18
16
9
9

9
4
2
2

5
0
0
2

2

1

0

0

Group Events, n (%) Median (95% CI), mo

D+T
Female
Male

78 (40)
99 (41)

NR (43.6-NR)
NR (41.5-NR)

0.56 (0.42-0.75)
0.45 (0.35-0.58)

-
-

PBO
Female
Male

108 (56)
146 (61)

25.5 (13.8-49.8)
13.8 (11.0-19.4)

D+T vs PBO
HR (95% CI)a

Data cutoff: April 30, 2018.
a HR was estimated using Pike estimator. An HR < 1 indicates a lower risk with dabrafenib + trametinib than with 
placebo.

• RFS benefit consistently favored dabrafenib + trametinib vs 
placebo across all T stages classified per AJCC 7th edition 
criteria (Figure 4)

 – T1: Median RFS was not reached in the dabrafenib + trametinib 
or placebo arms (HR, 0.42 [95% CI, 0.25-0.70])

 – T2: Median RFS was not reached in the dabrafenib + 
trametinib arm vs 22.1 months in the placebo arm (HR, 0.51 
[95% CI, 0.34-0.76])

 – T3: Median RFS was 44.5 months in the dabrafenib + trametinib 
arm vs 16.6 months in the placebo arm (HR, 0.55 [95% CI, 0.39-
0.77])

 – T4: Median RFS was 40.9 months in the dabrafenib + 
trametinib arm vs 8.6 months in the placebo arm (HR, 0.42 
[95% CI, 0.29-0.60])

Figure 4. Investigator-Assessed Kaplan-Meier RFS Curves by 
T stage

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

Time From Randomization, months

P
ro

p
o

rt
io

n
 A

liv
e

 a
n

d
 R

e
la

p
se

 F
re

e

32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62

74
108
140
106
83

102
128
106

D+T T1
D+T T2
D+T T3
D+T T4
PBO T1
PBO T2
PBO T3
PBO T4

No. at risk
70

102
133
99
79
92

120
85

70
100
128
98
69
78
98
69

68
98
125
91
62
70
85
55

67
95
121
90
56
67
81
51

67
94
117
87
54
62
71
48

65
91
112
81
51
55
65
42

63
87

104
76
49
50
60
38

60
85

100
74
49
50
57
36

56
77
90
70
44
48
54
33

53
73
87
65
43
47
50
32

52
72
85
63
43
46
49
31

52
68
80
59
41
44
46
31

50
67
78
58
41
42
46
31

50
63
77
56
41
41
45
31

49
62
73
55
41
38
45
29

49
61
70
54
41
38
45
28

49
59
69
53
40
37
43
26

48
59
68
49
40
35
42
25

48
59
67
48
40
34
41
25

46
48
47
39
33
31
34
25

38
44
44
32
28
26
31
22

36
38
41
30
27
25
29
21

28
31
29
24
19
20
23
15

23
27
21
19
16
15
18
12

19
18
13
13
11
11
13
8

12
13
11
9
8
5
7
6

9
7

10
6
4
3
7
3

1
3
5
3
1
0
1
2

1
1
2
0
1

1
0

0
0
1

0

1

0

0

T3
T4

63 (45)
49 (46)

44.5 (30.7-NR)
40.9 (26.8-NR)

0.55 (0.39-0.77)
0.42 (0.29-0.60)

-
-

PBO
T1
T2

38 (46)
57 (56)

NR (16.6-NR)
22.1 (11.5-41.3)

D+T
T1
T2

18 (24)
42 (39)

NR (NR-NR)
NR (38.9-NR)

0.42 (0.25-0.70)
0.51 (0.34-0.76)

Group Events, n (%) Median (95% CI), mo

-
-

T3
T4

77 (60)
75 (71)

16.6 (10.8-33.1)
8.6 (5.6-13.9)

D+T vs PBO
HR (95% CI)a

Data cutoff: April 30, 2018.
a HR was estimated using Pike estimator. An HR < 1 indicates a lower risk with dabrafenib + trametinib than with 
placebo.

• RFS was longer with dabrafenib + trametinib than with placebo 
across all N stages classified per AJCC 7th edition criteria 
(Figure 5)

 – N1: Median RFS was not reached in the dabrafenib + 
trametinib arm vs 33.1 months in the placebo arm (HR, 0.52 
[95% CI, 0.37-0.72])

 – N2: Median RFS was not reached in the dabrafenib + trametinib 
arm vs 12.2 months in the placebo arm (HR, 0.38 [95% CI, 0.28-
0.53])

 – N3: Median RFS was 24.2 months in the dabrafenib + 
trametinib arm vs 7.1 months in the placebo arm (HR, 0.58 
[95% CI, 0.41-0.83])

• RFS benefit favored dabrafenib + trametinib vs placebo 
regardless of the absence or presence of in-transit metastases 
(Figure 6)

 – In patients without in-transit metastases, median RFS was not 
reached in the dabrafenib + trametinib arm vs 17.2 months in 
the placebo arm (HR, 0.49 [95% CI, 0.40-0.60])

 – In patients with in-transit metastases, median RFS was 
45.6 months in the dabrafenib + trametinib arm vs 5.7 months 
in the placebo arm (HR, 0.45 [95% CI, 0.24-0.82])

Figure 5. Investigator-Assessed Kaplan-Meier RFS Curves by 
N stage

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

Time From Randomization, months

P
ro

p
o

rt
io

n
 A

liv
e

 a
n

d
 R

e
la

p
se

 F
re

e

32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62

169
159
110
176
158
97

D+T N1
D+T N2
D+T N3
PBO N1
PBO N2
PBO N3

No. at risk
163
148
102
169
139
78

161
144
100
151
112
58

155
140
96
130
100
50

151
138
92
127
89
47

147
135
90
119
82
42

143
128
83
111
70
38

134
123
78
104
63
36

129
120
75
101
62
35

121
112
65
95
57
33

115
106
60
91
55
32

113
103
59
90
53
32

110
100
52
86
51
31

107
99
50
86
50
30

105
96
48
85
49
30

103
94
45
81
48
29

101
91
45
80
48
29

99
90
44
76
48
27

96
89
42
74
47
26

96
88
41
72
47
26

78
70
35
64
40
24

71
60
30
53
36
23

66
53
29
50
36
21

52
37
25
41
25
14

48
24
20
30
21
12

34
16
15
21
16
7

22
13
12
14
7
6

18
7
9
8
5
5

7
2
4
2
0
2

2
0
3
1

1

0

2
0

1

0

0

N3 64 (58) 24.2 (19.3-40.8) 0.58 (0.41-0.83)

-
-

PBO
N1
N2

90 (51)
98 (62)

33.1 (19.6-57.9)
12.2 (8.3-17.3)

D+T
N1
N2

56 (33)
57 (36)

NR (NR-NR)
NR (47.9-NR)

0.52 (0.37-0.72)
0.38 (0.28-0.53)

Group Events, n (%) Median (95% CI), mo

-N3 65 (67) 7.1 (5.4-12.8)

D+T vs PBO
HR (95% CI)a

Data cutoff: April 30, 2018.
a HR was estimated using Pike estimator. An HR < 1 indicates a lower risk with dabrafenib + trametinib than with 
placebo.

Figure 6. Investigator-Assessed Kaplan-Meier RFS Curves by 
Status of In-Transit Metastases

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

Time From Randomization, months

P
ro

p
o

rt
io

n
 A

liv
e

 a
n

d
 R

e
la

p
se

 F
re

e

32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62

387
51

395
36

D+T: no
D+T: yes
PBO: no
PBO: yes

No. at risk
367
46

359
27

362
43

302
19

352
39

262
17

342
39

246
16

334
38
227
15

318
36

205
13

300
35
190
12

291
33
185
12

269
29
173
11

254
27
166
11

248
27
163
11

236
26
156
11

230
26
154
11

225
24
152
11

218
24
146
11

213
24
145
11

209
24
139
11

203
24
136
10

202
23
134
10

163
20
119
8

144
17

104
7

132
16
99
7

102
12
76
4

82
10
60
3

58
7
41
3

40
7

24
3

29
5
16
2

11
2
3
1

5
0
2
0

2

1

0

0

Group Events, n (%) Median (95% CI), mo

D+T
No
Yes

153 (40)
24 (47)

NR (NR-NR)
45.6 (19.1-NR)

0.49 (0.40-0.60)
0.45 (0.24-0.82)

-
-

PBO
No
Yes

229 (58)
25 (69)

17.2 (13.8-23.7)
5.7 (2.8-34.1)

D+T vs PBO
HR (95% CI)a

Data cutoff: April 30, 2018.
a HR was estimated using Pike estimator. An HR < 1 indicates a lower risk with dabrafenib + trametinib than with 
placebo.

Figure 7. Investigator-Assessed Kaplan-Meier RFS Curves by 
Histological Subtype (superficial spreading, nodular, other)

1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

Time From Randomization, months

P
ro

p
o

rt
io

n
 A

liv
e

 a
n

d
 R

e
la

p
se

 F
re

e

32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62

191
102
145
173
119
139

D+T superficial spreading
D+T nodular
D+T other
PBO superficial spreading
PBO nodular
PBO other

No. at risk
181
98
134
160
105
121

179
97
129
132
90
99

173
93
125
113
76
90

170
90
121
108
72
82

168
88
116
102
71
69

161
82
111
95
64
59

151
78
106
87
60
55

149
76
99
87
57
53

136
71
91
83
50
51

131
66
84
81
47
49

128
65
82
80
46
48

124
62
76
78
43
46

122
60
74
77
42
46

118
58
73
75
42
46

115
57
70
73
41
43

114
55
68
73
40
43

114
52
67
71
38
41

111
51
65
70
36
40

110
51
64
69
35
40

92
36
55
58
31
38

77
33
51
50
29
33

73
32
43
49
28
30

57
25
32
39
21
20

49
22
21
31
19
13

34
16
15
21
13
10

25
11
11
15
6
6

19
6
9
10
5
3

6
1
6
1
3
0

1
1
3
1
1

0
0
2
0
1

0

0

Other 62 (43) 47.9 (28.8-NR) 0.49 (0.36-0.69)

-
-

PBO
Superficial spreading
Nodular

93 (54)
77 (65)

24.4 (13.8-52.9)
16.5 (11.1-22.1)

D+T
Superficial spreading
Nodular

66 (35)
49 (48)

NR (NR-NR)
45.6 (28.8-NR)

0.48 (0.35-0.66)
0.53 (0.37-0.75)

Group Events, n (%) Median (95% CI), mo

-Other 84 (60) 11.0 (8.4-20.2)

D+T vs PBO
HR (95% CI)a

Data cutoff: April 30, 2018.
a HR was estimated using Pike estimator. An HR < 1 indicates a lower risk with dabrafenib + trametinib than with 
placebo.

• Dabrafenib + trametinib improved RFS vs placebo regardless of 
histological subtype (Figure 7)

 – In patients with nodular melanoma, median RFS was 45.6 
months in the dabrafenib + trametinib arm vs 16.5 months in 
the placebo arm (HR, 0.53 [95% CI, 0.37-0.75])

 – In patients with superficial spreading melanoma, median RFS 
was not reached in the dabrafenib + trametinib arm vs 
24.4 months in the placebo arm (HR, 0.48 [95% CI, 0.35-0.66])

Conclusions
• RFS benefit favored dabrafenib + trametinib in patients 

with completely resected stage III BRAF V600E/K– 
mutant melanoma vs placebo regardless of the 
following baseline factors, confirming previous findings1:

 – Age

 – Sex 

 – T stage

 – N stage

 – Status of in-transit 
metastases 

 – Histological subtype

• This updated analysis supports the use of dabrafenib 
+ trametinib regardless of clinical and pathological 
factors at treatment initiation

References
1. Hauschild A, et al. J Clin Oncol. 2018;36:3441-3449.

2. Long GV, et al. N Engl J Med. 2017;377:1813-1823.

3. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals 

Corporation; 2018.

4. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals 

Corporation; 2018.

5. Tafinlar (dabrafenib) [summary of product characteristics]. Camberley, UK: Novartis 

Pharmaceuticals UK Ltd; 2018. 

https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-

product-information_en.pdf. Accessed April 18, 2019.

6. Mekinist (trametinib) [summary of product characteristics]. Camberley, UK: Novartis 

Pharmaceuticals UK Ltd; 2019. 

https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-

product-information_en.pdf. Accessed April 18, 2019.

7. Dummer R, et al. ESMO 2018 [poster 1250P].

Acknowledgments
We thank the patients and their families for their participation. We also thank 
study site staff, additional investigators, and others for their contributions. 
We thank Maurizio Voi, MD (Novartis Pharmaceuticals Corporation), 
for guidance and critical review and Jorge J. Moreno-Cantu, MSc, PhD 
(Novartis Pharmaceuticals Corporation), for editorial assistance. This 
study was sponsored by GlaxoSmithKline; dabrafenib and trametinib are 
assets of Novartis AG as of March 2, 2015. We thank Zareen Khan, PhD, 
from ArticulateScience LLC, for medical editorial assistance with this 
presentation, which was funded by Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, in accordance with Good Publication Practice (GPP3) 
(https://www.ismpp.org/gpp3) guidelines and International Committee of 
Medical Journal Editors recommendations.

This was previously presented at the 2019 American Society of Clinical 
Oncology Annual Meeting

Text: Qf6c35
To: 8NOVA (86682) US Only 
+18324604729 North, Central and South Americas; Caribbean; China 
+447860024038 UK, Europe & Russia 
+46737494608 Sweden, Europe 

Scan this QR code
Copies of this poster 
obtained through Quick 
Response (QR) Code are for 
personal use only and may 
not be reproduced without 
permission from ASCO® 
and the author of this poster. 

Visit the web at:
http://novartis.medicalcongressposters.com/Default.aspx?doc=f6c35